|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of granulomatous lobular mastitis: an international multidisciplinary consensus(2021 edition)显示文摘Granulomatous lobular mastitis(GLM) is a rare and chronic benign inflammatory disease of the breast. Difficulties exist in the management of GLM for many front-line surgeons and medical specialists who care for patients with inflammatory disorders of the breast. This consensus is summarized to establish evidence-based recommendations for the management of GLM. Literature was reviewed using PubMed from January 1, 1971 to July 31, 2020. Sixty-six international experienced multidisciplinary experts from 11 countries or regions were invited to review the evidence.Levels of evidence were determined using the American College of Physicians grading system, and recommendations were discussed until consensus. Experts discussed and concluded 30 recommendations on historical definitions,etiology and predisposing factors, diagnosis criteria, treatment, clinical stages, relapse and recurrence of GLM. GLM was recommended as a widely accepted definition. In addition, this consensus introduced a new clinical stages and management algorithm for GLM to provide individual treatment strategies. In conclusion, diagnosis of GLM depends on a combination of history, clinical manifestations, imaging examinations, laboratory examinations and pathology.The approach to treatment of GLM should be applied according to the different clinical stage of GLM. This evidencebased consensus would be valuable to assist front-line surgeons and medical specialists in the optimal management of GLM. | Qian-Qian Yuan Shu-Yuan Xiao Omar Farouk Yu-Tang Du Fereshte Sheybani Qing Ting Tan Sami Akbulut Kenan Cetin Afsaneh Alikhassi Rami Jalal Yaghan Irmak Durur-Subasi Fatih Altintoprak Tae Ik Eom Fatih Alper Mustafa Hasbahceci David Martínez-Ramos Pelin Seher Oztekin Ava Kwong Cedric W.Pluguez-Turul Kirstyn EBrownson Shirish Chandanwale Mehran Habib Liu-Yi Lan Rui Zhou Xian-Tao Zeng Jiao Bai Jun-Wen Bai Qiong-Rong Chen Xing Chen Xiao-Ming Zha Wen-Jie Dai Zhi-Jun Dai Qin-Yu Feng Qing-Jun Gao Run-Fang Gao Bao-San Han Jin-Xuan Hou Wei Hou Hai-Ying Liao Hong Luo Zheng-Ren Liu Jing-Hua Lu Bin Luo Xiao-Peng Ma Jun Qian Jian-Yong Qin Wei Wei Gang Wei Li-Ying Xu Hui-Chao Xue Hua-Wei Yang Wei-Ge Yang Chao-Jie Zhang Fan Zhang Guan-Xin Zhang Shao-Kun Zhang Shu-Qun Zhang Ye-Qiang Zhang Yue-Peng Zhang Sheng-Chu Zhang Dai-Wei Zhao Xiang-Min Zheng Le-Wei Zheng Gao-Ran Xu Wen-Bo Zhou Gao-Song Wu | 2022 | Military Medical Research2022，9，4： | 13 |
| 2 | Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer:a randomized controlled trial显示文摘Background:Extensive studies have confirmed the efficacy of taxanes in combination with anthracycline-based chemotherapy on breast cancer.However,few studies have assessed the efficacy of weekly taxane-anthracycline regimens on locally advanced breast cancer.This study was to compare the efficacy and safety of a weekly taxaneanthracycline regimen with those of tri-weekly anthracycline-based regimen in patients with locally advanced breast cancer.Methods:Patients with locally advanced breast cancer were randomized to receive 4-6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracil-epirubicin-cyclophosphamide(FEC) regimen or weekly paclitaxel-epirubicin(PE) regimen.The primary endpoint was the pathologic complete response(pCR) rate.Other endpoints included the clinical tumor response,breast-conserving surgery rate,and adverse events.Results:Between March 2010 and September 2013,293 patients were randomized to the FEC(n=151) and PE(n=142) arms.The overall clinical response rate was significantly higher in the PE arm than in the FEC arm(76.06%vs.59.95%,P=0.001).Consistently,the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm(P<0.001).However,the pCR rate was similar in the two arms(10.61%vs.12.31%,P=0.665).Overall,36(27.27%) patients in the FEC arm and 6(35.28%) in the PE arm were qualified for breast-conserving surgery.Most adverse events were comparable in both arms,with more severe neutropenia in the PE arm than in the FEC arm(11.97%vs.5.96%,P=0.031).Conclusions:In patients with locally advanced breast cancer,weekly PE was not superior to FEC in terms of pCR.However,weekly PE has a higher response rate and superior down-staging effects.On this account,the PE regimen may be considered an alternative option for locally advanced breast cancer.Long-term follow-up data are needed to confirm the efficacy of this regimen on locally advanced breast cancer.Trial registration Chinese clinical trial registry,ChiCTR-TRC-10001043,September 21。 | Qiu-Wen Tan Ting Luo Hong Zheng Ting-Lun Tian Ping He Jie Chen He-Lin Zeng Qing Lv | 2017 | Chinese Journal of Cancer2017，36，6： | 5 |
| 3 | 中国胃癌患者肿瘤遗传易感基因的多中心研究显示文摘背景:10%的胃癌与遗传因素相关。然而,对中国胃癌患者遗传易感基因的认识仍极为匮乏。本研究旨在确定中国人群中具有遗传高危因素的胃癌患者的遗传易感基因突变频率和突变谱。方法:纳入来自中国7家中心具有家族遗传性高危因素的40例胃癌患者,采用二代测序技术检测先证者与癌症遗传易感性相关的171个基因。对于发现存在已知致病或疑似致病突变的先证者,使用一代测序技术对先证者及其血亲进行突变位点的进一步验证。结果:40例患者中,有25%(10/40)先证者发现了涉及9个不同基因的10种已知致病或疑似致病突变,包括1例CDH1,1例MLH1,1例MSH2,1例CHEK2,1例BLM,1例EXT2,1例PALB2,1例ERCC2突变,2例SPINK1。此外,在27例患者中发现了129个意义未明的突变。结论:本研究显示,在具备遗传高危因素的中国胃癌患者中,每4例患者就有1例存在遗传易感基因的已知致病或疑似致病胚系突变。本研究结果进一步表明,中国胃癌患者可能具有独特的遗传背景。 | Yin-Jie Zhang Yang Yang Qing Wei Ting Xu Xiao-Tian Zhang Jing Gao Si-Yi Tan Bao-Rui Liu Jing-Dong Zhang Xiao-Bing Chen Zhao-Jie Wang Meng Qiu Xin Wang Lin Shen Xi-Cheng Wang | 2021 | Gastroenterology Report2021，9，4： | 1 |
| 4 | 每周一次的紫杉烷–蒽环类联合方案与3周一次的以蒽环类为基础方案治疗局部晚期乳腺癌的随机对照研究显示文摘背景与目的已有大量研究证实了紫杉烷与蒽环类联合化疗治疗乳腺癌的疗效。然而,很少有研究评价每周一次紫杉烷–蒽环类治疗方案对局部晚期乳腺癌的疗效。本研究旨在比较每周一次紫杉烷–蒽环类治疗方案和3周一次以蒽环类为基础的治疗方案在治疗局部晚期乳腺癌上的疗效和安全性。方法局部晚期乳腺癌患者随机分组,接受4–6周期的3周一次的5-氟尿嘧啶–表柔比星–环磷酰胺(5-fluorouracil–epirubicin–cyclophosphamide,FEC)或每周一次的紫杉醇–表柔比星(paclitaxel–epirubicin,PE)的新辅助化疗方案。主要终点是病理完全缓解(pathologic complete response,pCR)率。其他终点包括临床肿瘤反应、保乳手术率和不良事件。结果从2010年3月至2013年9月,293例患者被随机分为FEC(n=151)组和PE(n=142)组。PE组的总临床反应率显著高于FEC组(76.06%vs. 59.95%,P=0.001)。一致的是,PE组化疗后病理性T和N分期显著低于FEC组(P <0.001)。但两组的pCR率是相似的(10.61%vs. 12.31%,P=0.665)。总体而言,FEC组36例(27.27%)和PE组6例(35.28%)适合进行保乳手术。两个治疗组中患者的大多数不良事件相似,其中PE组患者的中性粒细胞减少症比FEC组更严重(11.97%vs. 5.96%,P=0.031)。结论:在局部晚期乳腺癌患者中,每周一次PE方案在pCR方面并不优于每3周一次FEC方案。然而,每周一次PE方案具有较高的应答率和较好的肿瘤降级效果。因此,PE方案可能为治疗局部晚期乳腺癌的可选方案。还需要长期随访数据来证实这种方案对治疗局部晚期乳腺癌患者的疗效。 | Qiu-Wen Tan Ting Luo Hong Zheng Ting-Lun Tian Ping He Jie Chen He-Lin Zeng Qing Lv | 2018 | 癌症2018，37，2： | 1 |
| 5 | Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers显示文摘To The Editor I want to congratulate Dr.Tan and colleagues for their article entitled'Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer:a randomized controlled trial'[1].The pathologic complete response(pCR)rate was similar in the two arms(10.61%vs.12.31%,P=0.665).However,the | Kadri Altundag Qiu-Wen Tan Ting Luo Hong Zheng Ting-Lun Tian Ping He Jie Chen He-Lin Zeng Qing Lv | 2017 | Chinese Journal of Cancer2017，36，6： | 1 |
| 6 | Dynein axonemal heavy chain 10 deficiency causes primary ciliary dyskinesia in humans and mice显示文摘Primary ciliary dyskinesia(PCD)is a congenital,motile ciliopathy with pleiotropic symptoms.Although nearly 50 causative genes have been identified,they only account for approximately 70%of definitive PCD cases.Dynein axonemal heavy chain 10(DNAH10)encodes a subunit of the inner arm dynein heavy chain in motile cilia and sperm flagella.Based on the common axoneme structure of motile cilia and sperm flagella,DNAH10 variants are likely to cause PCD.Using exome sequencing,we identified a novel DNAH10 homozygous variant(c.589C>T,p.R197W)in a patient with PCD from a consanguineous family.The patient manifested sinusitis,bronchiectasis,situs inversus,and asthenoteratozoospermia.Immunostaining analysis showed the absence of DNAH10 and DNALI1 in the respiratory cilia,and transmission electron microscopy revealed strikingly disordered axoneme 9+2 architecture and inner dynein arm defects in the respiratory cilia and sperm flagella.Subsequently,animal models of Dnah10-knockin mice harboring missense variants and Dnah10-knockout mice recapitulated the phenotypes of PCD,including chronic respiratory infection,male infertility,and hydrocephalus.To the best of our knowledge,this study is the first to report DNAH10 deficiency related to PCD in human and mouse models,which suggests that DNAH10 recessive mutation is causative of PCD. | Rongchun Wang Danhui Yang Chaofeng Tu Cheng Lei Shuizi Ding Ting Guo Lin Wang Ying Liu Chenyang Lu Binyi Yang Shi Ouyang Ke Gong Zhiping Tan Yun Deng Yueqiu Tan Jie Qing Hong Luo | 2023 | Frontiers of Medicine2023，17，5： | 0 |
| 7 | Measurement of Br(n,γ)cross sections up to stellar s-process temperatures at the CSNS Back‑n显示文摘The neutron capture cross sections(n,γ)of bromine were obtained using the time-of-flight technique at the Back-n facility of the China Spallation Neutron Source.Promptγ-rays originating from neutron-induced capture events were detected using four C_(6)D_(6) detectors.The pulse-height weighting technique and double-bunch unfolding method based on Bayesian theory were used in the data analysis.Background deductions,normalization,and corrections were carefully considered to obtain reliable measurement results.The multilevel R-matrix Bayesian code SAMMY was used to extract the resonance parameters in the resolved resonance region(RRR).The average cross sections in the unresolved resonance region(URR)were obtained from 10 to 400 keV.The experimental results were compared with data from several evaluated libraries and previous experi-ments in the RRR and URR.The TALYS code was used to describe the average cross sections in the URR.The astrophysical Maxwell average cross sections(MACSs)of ^(79,81)Br from kT=5 to 100 keV were calculated over a sufficiently wide range of neutron energies.At a thermal energy of kT=30 keV,the MACS value for ^(79)Br 682±68 mb was in good agreement with the KADoNiS v1.0 recommended value.By contrast,the value of 293±29 mb for ^(81)Br was substantially higher than that of the evaluated database and the KADoNiS v1.0 recommended value. | Gao‑Le Yang Zhen‑Dong An Wei Jiang Xian‑Kai Li Wei‑Wei Qiu Zheng‑Fa Liao Zi‑Yue Zhuang Xiao‑Ping Zhang Sheng‑Li Chen Chen‑Chen Guo Er‑Xi Xiao Xiao Fang Xin‑Xiang Li Xin‑Rong Hu Bing Jiang Jin‑Cheng Wang Jie Ren Wen Luo Zhi‑Chao Zhu Hao‑Yang Lan Zong‑Wei Cao Xu Ma Ying‑Du Liu Pu‑Sen Wang Yi Yang Ping Su Xian‑Gai Deng Wan‑Bing He Chun‑Wang Ma Yu‑Ting Wang Zhi‑Tao Dai Peng‑Qin He Ren‑Guang Tang Tao Zhou Jing Wang Han Yi Yue Zhang Yong‑Hao Chen Rui‑Rui Fan Ke‑Qing Gao Qiang Li Kang Sun Zhi‑Xin Tan Min‑Hao Gu Han‑Tao Jing Jing‑Yu Tang | 2023 | Nuclear Science and Techniques2023，34，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员